Headlines about Bioverativ (NASDAQ:BIVV) have been trending somewhat positive on Friday, Accern Sentiment reports. Accern identifies positive and negative media coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Bioverativ earned a coverage optimism score of 0.17 on Accern’s scale. Accern also assigned news articles about the biotechnology company an impact score of 45.5826753876032 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

Here are some of the media stories that may have effected Accern’s rankings:

Bioverativ (NASDAQ:BIVV) traded up $1.04 during trading hours on Friday, hitting $63.75. 1,557,600 shares of the stock were exchanged, compared to its average volume of 1,110,000. The firm has a market capitalization of $6,900.00 and a price-to-earnings ratio of 15.59. Bioverativ has a twelve month low of $40.00 and a twelve month high of $64.68.

Bioverativ (NASDAQ:BIVV) last posted its quarterly earnings data on Thursday, October 26th. The biotechnology company reported $0.80 earnings per share for the quarter, beating analysts’ consensus estimates of $0.55 by $0.25. The business had revenue of $291.60 million during the quarter, compared to analyst estimates of $285.45 million. Bioverativ had a net margin of 40.44% and a return on equity of 69.03%. The business’s quarterly revenue was up 27.2% on a year-over-year basis. sell-side analysts forecast that Bioverativ will post 2.48 earnings per share for the current year.

BIVV has been the subject of a number of research reports. Zacks Investment Research upgraded shares of Bioverativ from a “hold” rating to a “buy” rating and set a $60.00 target price for the company in a research report on Monday, January 1st. Argus upgraded shares of Bioverativ from a “hold” rating to a “buy” rating and set a $64.00 target price for the company in a research report on Wednesday, September 20th. Deutsche Bank set a $53.00 target price on shares of Bioverativ and gave the stock a “hold” rating in a research report on Monday, November 20th. Piper Jaffray Companies reissued an “overweight” rating and issued a $71.00 price objective on shares of Bioverativ in a research report on Monday, October 23rd. Finally, Royal Bank of Canada began coverage on shares of Bioverativ in a research report on Thursday, September 14th. They issued a “sector perform” rating and a $59.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company’s stock. Bioverativ presently has a consensus rating of “Hold” and an average target price of $60.47.

ILLEGAL ACTIVITY NOTICE: “Bioverativ (BIVV) Earning Somewhat Positive News Coverage, Study Finds” was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece of content on another publication, it was illegally stolen and republished in violation of U.S. & international copyright & trademark law. The legal version of this piece of content can be accessed at https://www.thecerbatgem.com/2018/01/12/bioverativ-bivv-earning-somewhat-positive-news-coverage-study-finds.html.

Bioverativ Company Profile

Bioverativ Inc (Bioverativ) is a biotechnology company. The Company is focused on the discovery, research, development and commercialization of therapies for the treatment of hemophilia and other blood disorders. It markets approximately two products, including ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein], and ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], extended half-life clotting-factor therapies for the treatment of hemophilia A and hemophilia B, respectively.

Insider Buying and Selling by Quarter for Bioverativ (NASDAQ:BIVV)

Receive News & Ratings for Bioverativ Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioverativ and related companies with MarketBeat.com's FREE daily email newsletter.